To offer evidence-based clinical recommendations concerning prognosis in advanced cancer patients.
INTRODUCTION
Besides being one of the core skills in the practice of medicine, 1,2 prognostication in advanced cancer has special importance. In advanced phases of the disease, prognostication cannot be based on the same information as in earlier stages, when it is typically based on tumor stage. [3] [4] [5] However, accurate prediction of survival is still necessary for clinical, organizational, and ethical reasons, especially in helping to avoid harm, discomfort, and inappropriate therapies in vulnerable patients 6 and, conversely, in planning specific care strategies. Additionally, important personal decisions are influenced by prognostic information, and therefore, patients' autonomy can be enhanced by providing better prognostication within the context of appropriate communication. [7] [8] [9] Prognostic accuracy in this population seems to be the exception rather than the rule. A large prospective cohort study, involving 343 doctors and 468 hospice outpatients, found that only 20% of prognoses were accurate and that, overall, doctors overestimated survival by a factor of approximately 5. 10 Therefore, the Research Network of the European Association for Palliative Care decided to establish a Working Group (WG) with the aim of providing evidence-based recommendations on the use of prognostic factors to determine length of survival in advanced cancer patients.
METHODS
The WG reviewed several sources describing the clinical guidelines development process, [11] [12] [13] [14] and the following steps were adopted: (1) defining group membership; (2) identifying the target population; (3) defining the key questions; (4) systematically searching the literature; (5) assigning the level of evidence to the selected literature; and (6) formulating and grading the final recommendations.
Defining Group Membership
WG members were identified on the basis of their clinical experience in palliative care and in prognostic cancer studies (M.M., A.C., N.C., S.E., P.G., M.N., and A.V.). Members with epidemiologic and statistical expertise were also enlisted (C.B., P.G., and A.V.), and the contribution of an experienced nursing person was ensured (P.L.). Practical and ethical considerations determined the exclusion of patients. Sociologic and philosophical points of view were available (B.B. and N.C.). Finally, the group conclusions were submitted to external reviewers (F.D.C., G.H., and S.K.) and to the Steering Committee of the European Association for Palliative Care Research Network.
Identifying the Target Population
Accepted criteria for staging advanced cancer patients are lacking. Some authors have attempted to describe, with subjective criteria, inception cohorts, [15] [16] [17] [18] [19] whereas others have examined patient populations referred to a palliative care program. 20, 21 However, many studies have shown that the median survival in populations of advanced cancer patients undergoing palliative care is less than 90 days. 15, [22] [23] [24] For these reasons, only populations homogeneous by survival (survival cohort) 25 were included by selecting studies in which the median survival of the group was Յ 90 days, excluding surgical series.
Defining the Key Questions
The WG defined six key questions, which developed into recommendations, that were assigned to different pairs of group members to carry out a literature search and analyze the available evidence about the usefulness of an accurate prognostication of life expectancy in advanced cancer patients, the prognostic role of clinical signs and symptoms, psychosocial characteristics, laboratory parameters, and prognostic scores.
Systematic Literature Search
Systematic reviews were performed for each area of interest. The search for relevant articles was performed on the Medline and Embase databases. The search strategy is presented in Table 1 . A hand search of the References section of electronically identified articles was also performed. Articles not based on original data (unless formal meta-analyses) were excluded. A formal meta-analysis was not conducted because of the great heterogeneity of the combinations of different prognostic factors examined, 17, 26, 27 poor quality of published studies, and frequent lack of minimal standards in reporting results. The prognostic strength of each predictor examined was described considering the hazard ratios and their CIs. A detailed report of all the hazard ratios and their CIs will be presented elsewhere.
Assigning the Level of Evidence to the Selected Literature
The level of evidence attributed to the results from each study was based on the methodologic quality of the study and on the study type.
11-13 A quality assessment checklist, based on the existing literature, 12,28-35 was formulated (Table 2 ). When evaluating meta-analyses, homogeneity of results was required to ensure quality. The study type classifications are listed in Table 3 .
12,29,31 Quality and study type classification levels were combined to give the final level of evidence (Table 4 , modified from the Centre for Evidence Based Medicine Web site).
12 Each study was evaluated independently by at least two group members.
Formulating and Grading the Final Recommendations
The evidence available for each topic, graded as shown in Table 4 , was developed into draft recommendations by a writing committee, circulated to the full WG and to the external reviewers, and finalized into the present format.
RESULTS
The literature review produced a list of publications, which are listed in Table 5 , that show the quality and characteristics of the evidence that was used to formulate the following recommendations (listed in brief in Table 6 ).
Recommendations
Recommendation 1. In the management of the patient with advanced cancer, physicians should base their decisions about therapeutic interventions and the place and type of care on the preferences and expectations of patients and their care givers as well as the life expectancy of the patient. Prognosis will sometimes determine access to specialist services, and an accurate estimate of life expectancy will generally facilitate decision making both for professional care givers and for patients and their families (grade D).
There is no study on prognostic factors aimed at evaluating whether an accurate prediction of survival can improve actual clinical care; that is, there is no impact study concerning the role of prognostic tools in improving decision making in the palliative care of advanced cancer. Despite this, it is the opinion of the WG that increased prognostic accuracy would assist health professionals to improve their care strategy and help patients and families to make more informed choices.
10,22,23,65
Recommendation 2. The Clinical Prediction of Survival (CPS) is a generally useful and valid tool but is subject to a series of factors that limit its accuracy. The CPS should not be used alone but in conjunction with other prognostic factors (grade A).
CPS could be defined as clinical prognostic judgment; Table 3 . Classification of Study Type 1. Impact studies: studies aiming at evaluating the clinical benefit of implementing a prognostic strategy; these studies should have a randomized controlled design 2. Formal meta-analysis of cohort studies 3. Confirmative cohort studies: the main aim is to evaluate the agreement between actual and predicted survival by the prospective application of indices and/or to test if a prognostic model still maintains its strength in a different sample of patients 4. Explorative cohort studies: the main aim is to examine how the predictive power of a new prognostic factor relates to those factors already available and/or to estimate the magnitude of its effect 5. Investigative cohort studies: the main aim is to investigate the association of putative new factors with survival 6. Nonanalytic studies (case reports/case series) it is subjective and depends on the clinician's assessment of the individual patient at the bedside or in the clinic. The prognostic value of CPS has received a great deal of criticism in the literature because of the characteristics previously mentioned and because of its inherent nonreproducibility. Our systematic review of the literature on CPS resulted in the selection of 27 articles, 11 of which were excluded. In the 16 eligible studies, 10,15,16,18,20,36-46 the correlation coefficient of CPS/actual survival varied between 0.2 and 0.65. In all the studies examined in a review published in 2000, CPS was reported as having an independent effect when used with most other prognostic factors or tools.
5 When using CPS, physicians need to be aware that it is subject to a series of features and shortcomings that limit its prognostic capacity. CPS is more than twice as likely to be overoptimistic versus overpessimistic and to overestimate the length of actual survival by a factor of between 3 and 5 (grade A). 26 CPS is subject to the Horizon Effect 24,66,67 (grade B), which is a term taken from the language of weather forecasting and used in clinical prognostication to mean the greater accuracy of short-term predictions over longterm predictions. Therefore, repeated evaluations of CPS at fixed intervals may be opportune (grade A). Considering CPS as a probability rather than a temporal value would ensure a greater accuracy (grade A). Lack of experience in oncology and palliative care reduces accuracy, and thus, a second opinion by a more experienced professional could be useful (grade D). A second opinion could also be worth obtaining if the first physician has a close relationship with the patient (grade B).
Clinicians should consider using CPS in combination with other prognostic factors or scores to improve the accuracy of their predictions (grade A). Training in prognostication could improve the accuracy of CPS (grade D).
Recommendation 3.
Certain clinical signs and symptoms have proven to be prognostically significant in this patient population, the most important of which are performance status (grade B), some symptoms of the cancer anorexia-cachexia syndrome (CACS; grade B), dyspnea (grade B), and delirium or cognitive failure (grade B). Factors linked to the patient or to the primary/metastatic site and biologic characterization of the tumor do not seem to be prognostically important in advanced cancer, as defined in this review. 15, 16, 18, [47] [48] [49] [50] Conversely, a correlation between some clinical signs and symptoms and survival has been confirmed in numerous multivariate analyses. In this section, of the 80 works analyzed, the 20 studies considered 15, 16, 18, 20, 37, 40, [47] [48] [49] [50] [51] [52] [53] [54] [55] [56] [57] [58] [59] [60] show that performance status 18,37,40,47,51,52,54,57,59 and various indices of activity and functional autonomy 15, 16, 49, 50, 53, 55 are prognostically significant. In particular, low performance status is considered a reliable prognostic factor to predict short-term survival. However, initially high scores are not necessarily predictive of a long survival, whereas their deterioration often indicates a serious worsening of the prognosis. Signs and symptoms characterizing a clinical condition that is often termed the common terminal pathway, 54 Other signs and symptoms (nausea, constipation, dizziness, anxiety, depression, fever, pain, diarrhea, hemorrhage, Clinicians can make use of some easily applicable prognostic scores to make a rapid prediction capable of identifying classes of patients with significantly different life expectancies (grade A) At the moment, the Palliative Prognostic Score is the more readily available system including most of the factors (grade A) Recommendation 6
Establishing a prognosis is part of the therapeutic alliance; patients have the right to be informed or not to be informed about their prognosis Using and communicating prognostic information should be within the context of a comprehensive, individualized, patient-centered approach (grade D)
pulse, and respiratory rate), polymorbidity, opioid therapy, and therapeutic and diagnostic interventions 18, 20, 47, 50, 52, 54, 59 have occasionally proven to be significant, mainly in less advanced stages of the disease. However, these symptoms have not been confirmed in multivariate analysis, especially in the far advanced patient population. The prognostic capacity of subjective indicators of quality of life or other psychological parameters is somewhat contradictory. Although they are certainly relevant in the earlier stages of disease, 71-78 the prognostic relevance of multidimensional tools in patient populations with a median survival of 90 days or less seems to be attributable to the physical-symptomatic component of the test.
15,56
Recommendation 4. There is some evidence that abnormalities in certain laboratory tests (particularly leukocytosis, lymphocytopenia, and elevated C-reactive protein) have prognostic significance (grade B). The need for a blood sample also needs to be weighed against the likely clinical advantage for the individual patient (grade D). Biologic parameters have not been as widely investigated as clinical parameters in this population of patients, 5 and a more accurate evaluation of these variables in relation to prognosis is undoubtedly warranted.
In the present review, a total of 23 biologic factors were studied in the nine works 16,42,47,54,59,61-64 selected for assessment. Laboratory parameters that proved significant in at least one multivariate analysis were low pseudocholinesterase, 61 high vitamin B 12 , 63 and high bilirubin. 54 Statistical significance in more than one study was observed for elevated C-reactive protein, 63,64 lymphocytopenia, 42,61 and leukocytosis.
42,61 The same biologic parameters also proved to be prognostically valid in other heterogeneous populations of patients with less advanced disease. This positive relationship was, conversely, lost by some factors, such as low serum albumin, in the patient population evaluated in the present study. For some factors, such as albumin and prealbumin levels, this could be attributed to a close correlation with other CACS characteristics that maintain their significance, to the detriment of weaker factors.
Recommendation 5. A number of prognostic scores or indices have been developed that are easy to use and permit a rapid estimate of life expectancy by placing patients into broad groups that differ significantly in survival (grade A). Some authors have built and validated prognostic scores for patients in palliative care programs. These scores are constructed on the basis of prognostic factors that have proven to be significant in multivariate analysis and have been validated quantitatively on the basis of their individual prognostic weight.
Only eight of the 24 studies identified satisfied the review requirements. Of these studies, four involved construction and development of scores, [19] [20] [21] 42 whereas four concerned the validation of two of the scores, the Palliative Prognostic (PaP) Score and the Palliative Prognostic Index (PPI). 43, 44, 58, 62 The PaP Score (Table 7) was built and validated in two independent multicenter population studies and is the only measure to include some simple biologic factors that require a blood sample. It has been validated in several countries, in various settings, and in different disease phases. 23, 42, 43, 58, 62 This score includes CPS, which means that it is used together with, rather than instead of, clinical judgment. The PaP Score was not constructed to include hematologic malignancies and, therefore, cannot be used in this patient population. Furthermore, the score does not include delirium, which was subsequently demonstrated to subdivide each population categorized by the PaP Score into two further prognostic subgroups.
58
The PPI does not include CPS, and one study specifically aimed at evaluating the impact of PPI on CPS 44 showed a significant improvement in prognostication. No studies have ever been conducted to compare the efficacy of different scores.
Recommendation 6. Establishing an accurate prognosis is part of the therapeutic alliance. Patients have a right to be informed of their prognosis or, if they prefer, not to be informed. Using and communicating prognostic information NOTE. The risk groups and total scores were as follows: group A: 30-day survival probability of Ͼ 70%, score ϭ 0 to 5.5; group B: 30-day survival probability of 30% to 70%, score ϭ 5.6 to 11.0; and group C: 30-day survival probability of Ͻ 30%, score ϭ 11.1 to 17.5.
should be within the context of a comprehensive, individualized, patient-centered approach (grade D).
A number of principles should be applied to this clinical situation. First, do not be a burden to the patient. From an ethical point of view, it is important that prognostic tools do not impose an additional burden on the patient, be it directly or indirectly (ie, by being time consuming and, thus, leaving less time for other aspects of patient care).
Second, use prognostic information within an ethically valid approach. It is important to understand that a prognosis is established, used, and communicated. Although our recommendations concentrate on establishing a prognosis, we should not forget that, once established, a prognosis should be used in an appropriate way. Treatment decisions should be based on a number of variables, including prognosis, and all these variables should receive due attention. The fact that prognostic information is, by definition, probabilistic, and that even the best prognostication will be dramatically inaccurate for a significant number of patients provides an additional reason for never losing sight of the patient and his or her individual trajectory and personal history. Prognostication that is not deeply embedded in an open, flexible, patient-centered, and dialogic approach is potentially dangerous.
Third, communicate prognosis when requested and in an appropriate way. Patients have a right to be informed about their prognosis, but they also have the right to refuse to be informed. When prognosis is communicated, ethical, cultural, religious, and psychological considerations are of fundamental importance to avoid inflicting additional harm to the patient.
Fourth, place emphasis on a holistic therapeutic approach beyond time limits. It is only by working within the realms of multidisciplinary palliative care and by continuing to consider the individual value of the patient's residual life that life expectancy prognostication can improve and further personalize the care of advanced cancer patients.
DISCUSSION
The recommendations made here are confined to a population of patients with advanced cancer and a median survival of no more than 90 days. The WG demonstrated that, given the available literature evidence, prognostication of life expectancy in advanced cancer patients is feasible and facilitated by the use of clinical tools such as signs and symptoms, laboratory examinations, and prognostic scores. In particular, strong evidence of prognostic significance has emerged for CPS, performance status, clinical symptoms of CACS (anorexia, weight loss, dysphagia, and xerostomia), dyspnea, delirium, some biologic factors (leukocytosis, Multidimensional quality-of-life questionnaires; it is possible that their prognostic capacity is a result of the identifying component of physical symptoms contained within them lymphocytopenia, and C-reactive protein level), and prognostic scores (Table 8) .
More research is needed to deepen our understanding of the processes leading to clinical prediction and of how it can be improved and refined by the help of other explicit, objective evaluations. 79, 80 The lack of evidence from impact studies supporting the usefulness of better prognostic tools for advanced cancer patients should also be underlined as an urgent area for research. Therefore, health workers involved in the care of advanced cancer patients are encouraged to use their clinical skills, together with evidence-based recommendations, to elaborate their own prediction of individual patient survival. The systematic use of prognostic scores can teach clinicians to focus their attention on prognosis and, at the same time, help in the clinical management of the patient. Therefore, these scores can be considered useful tools for health workers in clinical practice.
It is important to point out that prognostic information should not be limited to palliative care populations, but it can also be used to gain a better understanding of patient survival before referral for palliative care. More studies on well-defined inception cohorts are needed to improve our knowledge in this field.
Finally, it is clear to the WG that ethical considerations regarding prognostication at the end of life are indeed of fundamental importance. The failure to prognosticate or to prognosticate accurately can, in some circumstances, be as harmful as a mistaken diagnosis or therapy. The fallibility of prognosis alone highlights its moral dimensions.
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